Acute phase proteins and prognosis in multiple myeloma

Area of Science:

• Biochemistry
• Oncology
• Immunology

Background:

• Interleukin-6 (IL-6) influences disease severity and prognosis in plasma cell dyscrasias.
• IL-6 is a key regulator of the human acute phase response.
• Serum acute phase proteins (s.APP) may impact survival in multiple myeloma.

Purpose of the Study:

• To assess the impact of major serum acute phase proteins (s.APP) on survival in previously untreated myeloma patients.
• To identify prognostic biomarkers for multiple myeloma.
• To stratify patients based on survival predictions.

Main Methods:

• Univariate and multivariate Cox proportional hazard models were used.
• Analysis included 103 consecutive, previously untreated myeloma patients.
• Evaluated serum levels of C-reactive protein (s.CRP), alpha-1-antitrypsin (s.AAT), haptoglobin, acid alpha-1-glycoprotein, and alpha-2-macroglobulin (control).

Main Results:

• Univariate analysis revealed s.AAT and s.CRP significantly correlated with survival.
• Multivariate analysis identified s.beta-2-microglobulin (s.b2M), s.calcium, s.creatinine, BM plasma cell percentage, age, and s.AAT as significant survival predictors.
• Combining s.b2M and s.AAT levels stratified patients: low levels (< or = 3 mg/l and < or = 3 g/l, respectively) had excellent prognosis (median survival >10 years), while high levels had a median survival of 2.5 years.

Conclusions:

• Serum alpha-1-antitrypsin (s.AAT) is a significant prognostic biomarker in multiple myeloma.
• A combination of s.beta-2-microglobulin (s.b2M) and s.AAT provides effective risk stratification for myeloma patients.
• These biomarkers can aid in predicting survival outcomes and guiding treatment strategies.